“Moderna (MRNA) stock nearly tripled Wednesday after its Merck (MRK)-partnered cancer vaccine succeeded in a late-stage study of patients with melanoma… Moderna stock soared 177%, closing at 174.38. That’s a three-year high. Merck stock also jumped 12.6% to 152.20, hitting a record high…”… Continue Reading…